NCT07343193 Deprescribing Antipsychotics: a Multiple Case Study
| NCT ID | NCT07343193 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | Psychotic Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-09-09 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2025-09-09 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The literature on antipsychotic deprescribing highlights the difficulty in establishing a clear consensus on the most optimal strategy due to the diversity of clinical situations encountered in daily practice: who should be deprescribed, when, at what rate, what strategy to employ in case of relapse, etc. The fear of relapse leads psychiatrists (particularly in France) to tend to maintain long-term treatment, even if the arguments for this maintenance may be debatable due to an uncertain benefit-risk balance. Conversely, patients often request a reduction or discontinuation, notably because of the side effects of the treatments. This argument serves to justify the value of presenting unique clinical situations like those in this study in a publication. The goal is for readers to gain a practical understanding of the successes and difficulties of deprescribing in real-life situations.
Eligibility Criteria
Inclusion Criteria: * Adults (≥18 years) * Patients with a psychotic or related disorder * Patients on long-term antipsychotic treatment, clinically stable, who accept or request a deprescription between January 1, 2021, and October 30, 2025 Exclusion Criteria: \- Patients who have expressed their opposition to participating in the study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07343193 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Psychotic Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07343193 currently recruiting?
Yes, NCT07343193 is actively recruiting participants. Contact the research team at fabrice.berna@chru-strasbourg.fr for enrollment information.
Where is the NCT07343193 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT07343193 clinical trial?
NCT07343193 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 30 participants.